Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

S Nakhoda, A Vistarop, YL Wang - British journal of …, 2023 - Wiley Online Library
Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of
chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and …

Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities

AP Kater, C Owen, C Moreno, G Follows… - NEJM …, 2022 - evidence.nejm.org
Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

J Zhang, X Lu, J Li, Y Miao - Biomarker Research, 2022 - Springer
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic
leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib …

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a …

CU Niemann, T Munir, C Moreno, C Owen… - The Lancet …, 2023 - thelancet.com
Background In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior
progression-free survival versus chlorambucil–obinutuzumab in patients with previously …

Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW …

T Munir, C Moreno, C Owen, G Follows… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE In GLOW, fixed-duration ibrutinib+ venetoclax showed superior progression-free
survival (PFS) versus chlorambucil+ obinutuzumab in older/comorbid patients with …

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

N Jain, LJ Croner, JN Allan, T Siddiqi, A Tedeschi… - Clinical Cancer …, 2024 - AACR
Abstract Purpose: Mutations in BTK, PLCG2, and BCL2 have been reported in patients with
progressive disease (PD) on continuous single-agent BTK or BCL2 inhibitor treatment. We …

Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia

JN Allan, IW Flinn, T Siddiqi, P Ghia, CS Tam… - Clinical Cancer …, 2023 - AACR
Purpose: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic
lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized …

Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma

SA Setiawan, WZ Liu, PW Weng, CH Lee… - European Journal of …, 2023 - Elsevier
Double-hit lymphoma (DHL) is an aggressive subset of Diffuse Large B-cell Lymphoma
(DLBCL) with poor outcomes and without satisfying treatment options. BTK inhibitor …

Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia

AH Lipsky, N Lamanna - Cancer, 2023 - Wiley Online Library
Targeted therapies have revolutionized the frontline treatment landscape for patients with
chronic lymphocytic leukemia (CLL) and have largely displaced a reliance on …

Characterization of the Intraclonal Complexity of Chronic Lymphocytic Leukemia B Cells: Potential Influences of B-Cell Receptor Crosstalk with Other Stimuli

AN Mazzarello, M Fitch, M Cardillo, A Ng, S Bhuiya… - Cancers, 2023 - mdpi.com
Simple Summary Chronic lymphocytic leukemia (CLL) clones contain cells differing in age:
recently born, proliferative (PF), intermediate (IF), and resting (RF) fractions. We used …